Combatting Fibrosis: Exosome‐Based Therapies in the Regression of Liver Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Hepatic fibrosis results from chronic injury and inflammation in the liver and leads to cirrhosis, liver failure, and portal hypertension. Understanding the molecular mechanisms underlying hepatic fibrosis has advanced the prospect of developing therapies for regression of the disease. Resolution of fibrosis requires a reduction of proinflammatory and fibrogenic cytokines, a decrease in extracellular matrix (ECM) protein production, an increase in collagenase activity, and finally, a disappearance of activated myofibroblasts. Exosomes are nanovesicles of endocytic origin secreted by most cell types. They epigenetically reprogram and alter the phenotype of their recipient cells and hold great promise for the reversal of fibrosis. Recent studies have shown that exosomes function as conduits for intercellular transfer and contain all the necessary components to induce resolution of fibrosis, including the ability to (1) inhibit macrophage activation and cytokine secretion, (2) remodel ECM production and decrease fibrous scars, and (3) inactivate hepatic stellate cells, a major myofibroblast population. Here, we discuss the research involving the regression of hepatic fibrosis. We focus on the newly discovered roles of exosomes during fibrogenesis and as a therapy for fibrosis reversal. We also emphasize the novel discoveries of exosome‐based antifibrotic treatments in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationThe extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334 · cited 1×
“The ECM represents a noncellular component in the liver that is mainly composed of proteins and proteoglycans.(35) It forms an intricate network that provides a physical scaffold for cellular support”
BackgroundCommunication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444 · cited 1×
“They contain proteins and other molecules that reflect the transcriptional and/or translational activity of the cell of origin.(19) The differential contents of RNAs, proteins, lipids, and metabolites in exosomes are distinct to the cell type of origin.”
BackgroundSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 2×
“Various types of macrophages, such as M1 (inflammatory), M2a-like (profibrotic), and Mregulatory/M2c-like (regulatory), (73,75-77,80,81) are recruited during fibrogenesis, resulting in reepithelization, healing, or pathologic scarring.”
BackgroundMacrophage Polarization Comes of Age
Mantovani, Sica, & Locati, M. (2005) · Immunity · doi:10.1016/j.immuni.2005.10.001 · Cited by 1,259 · cited 1×
“Various types of macrophages, such as M1 (inflammatory), M2a-like (profibrotic), and Mregulatory/M2c-like (regulatory), (73,75-77,80,81) are recruited during fibrogenesis, resulting in reepithelization, healing, or pathologic scarring.”
BackgroundHepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 2×
“Recurrent epithelial injury is a prominent driving factor in the pathogenesis of progressive fibrosis(26) and results in hepatocyte dysfunction, which can occur through apoptosis.(26,27) Hepatocytes, in response to the hostile environment, undergo apoptosis through an extrinsic death receptor-mediated pathway, or alte…”
BackgroundModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
History, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells
Geerts, A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17550 · Cited by 740
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
Radaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610 · cited 1×
“Chronic inflammation and fibrosis are inextricably linked through the interactions among immune cells.(69-72) Macrophages play an important role in inflammation and subsequent fibrogenesis.”
BackgroundChiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535 · cited 2×
“(65-68) However, unlike HSCs, PFs respond to stimulation with taurocholic acid and IL-25, leading to an induction of Colα1(I) and IL-13, respectively.(64) Although PFs play a critical role in the pathogenesis of cholestatic liver fibrosis, functional properties of PFs and the mechanism by which PFs contribute to chole…”
BackgroundSelf-citationKhalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505
IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370
Attenuated liver fibrosis in the absence of B cells
Novobrantseva, T. I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24798 · Cited by 277
Portal fibroblasts: Underappreciated mediators of biliary fibrosis†
Dranoff, J. A., & Wells, R. G. (2010) · Hepatology · doi:10.1002/hep.23405 · Cited by 273
Povero, D., Panera, N., Eguchi, A., Johnson, C. D., Papouchado, B. G., de Araujo Horcel, L., Pinatel, E. M., Alisi, A., Nobili, V., & Feldstein, A. E. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.07.007 · Cited by 221
miR-21 Regulates Skin Wound Healing by Targeting Multiple Aspects of the Healing Process
Wang, T., Feng, Y., Sun, H., Zhang, L., Hao, L., Shi, C., Wang, J., Li, R., Ran, X., Su, Y., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.022 · Cited by 192
Seo, W., Eun, H. S., Kim, S. Y., Yi, H., Lee, Y., Park, S., Jang, M., Jo, E., Kim, S. C., Han, Y., et al. (2016) · Hepatology · doi:10.1002/hep.28644 · Cited by 175
Resolution of Liver Fibrosis: Basic Mechanisms and Clinical Relevance
Ramachandran, P., Iredale, J., & Fallowfield, J. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550057 · Cited by 129
Cited by
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
Hou, X., Yin, S., Ren, R., Liu, S., Yong, L., Liu, Y., Li, Y., Zheng, M., Kunos, G., Gao, B., et al. (2021) · Hepatology · doi:10.1002/hep.31658 · Cited by 223
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“Exosomes released into the serum might be useful antifibrotic tools [214].”
BackgroundBeyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
“…carriers to transport siRNAs or miRNAs to macrophages, reprogramming their activity [28,131] reducing, for instance, CCL2/TGF-β signalling [132,133] or nanoparticle-mediated approaches designed to selectively target hepatic macrophages with polarizing agents, improving specificity and…”
Metadata
- Authors
- Chen, L., Brenner, D. A., & Kisseleva, T.
- Venue
- Hepatology Communications
- Published
- 2018-12-13
- Volume
- 3
- Issue
- 2
- Pages
- 180-192
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2905551816
- Cited by
- 91
- References
- 21
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.